HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Authors
Keywords
-
Journal
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
Volume 68, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-09
DOI
10.1007/s00005-019-00566-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors
- (2019) G. Travis Clifton et al. CLINICAL IMMUNOLOGY
- HER2-Based Immunotherapy for Breast Cancer
- (2018) Naipeng Cui et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice
- (2018) Nastaran Barati et al. CANCER LETTERS
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer
- (2018) Atefeh Arab et al. CURRENT PHARMACEUTICAL DESIGN
- Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine
- (2018) Wei Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Developing anti-HER2 vaccines: Breast cancer experience
- (2018) Aydah Al-Awadhi et al. INTERNATIONAL JOURNAL OF CANCER
- Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
- (2018) Hester A. Doyle et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The viral approach to breast cancer immunotherapy
- (2018) Atefeh Arab et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- (2018) Babak Nami et al. Cancers
- An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells
- (2018) Michele Tomasicchio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response
- (2017) Atefeh Arab et al. IMMUNOLOGIC RESEARCH
- Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer
- (2017) Nastaran Barati et al. IMMUNOLOGY LETTERS
- A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice
- (2017) Atefeh Arab et al. JOURNAL OF DRUG TARGETING
- An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells
- (2017) Rezvan Yazdian-Robati et al. MICROCHIMICA ACTA
- Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth
- (2017) Paul D. Bryson et al. VACCINE
- Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer
- (2017) Henry W. C. Leung et al. Expert Review of Pharmacoeconomics & Outcomes Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03
- (2017) L. C. Benavides et al. JOURNAL OF CLINICAL ONCOLOGY
- Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model
- (2017) Atefeh Razazan et al. PLoS One
- Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
- (2017) Ahrong Kim et al. Scientific Reports
- Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer
- (2016) Min Su et al. Asian Pacific Journal of Cancer Prevention
- A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
- (2016) Giuseppe Curigliano et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical Development of the E75 Vaccine in Breast Cancer
- (2016) Guy T. Clifton et al. Breast Care
- Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells
- (2016) Zh. K. Nazarkina et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Improved Survival of HER2+Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
- (2016) Keith L. Knutson et al. CANCER RESEARCH
- A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice
- (2016) Thi Tran et al. CLINICAL CANCER RESEARCH
- Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
- (2016) Xu Zhou et al. CURRENT DRUG METABOLISM
- Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential
- (2016) Lucy M De La Cruz et al. Immunotherapy
- Phage display-derived human antibodies in clinical development and therapy
- (2016) André Frenzel et al. mAbs
- Antitumor immunity and advances in cancer immunotherapy
- (2016) Tomoharu Sugie et al. Breast Cancer
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
- (2016) Elizabeth A. Mittendorf et al. Oncotarget
- Immunotherapy in Breast Cancer
- (2016) Frederik Marmé Oncology Research and Treatment
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer
- (2016) Jashodeep Datta et al. JAMA Oncology
- Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence
- (2015) Beth A Mittendorf et al. CANCER RESEARCH
- Natural and therapy-induced immunosurveillance in breast cancer
- (2015) Guido Kroemer et al. NATURE MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization
- (2015) Fateme Sadri-Ardalani et al. TUMOR BIOLOGY
- Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12
- (2015) Erica N Bozeman et al. Human Vaccines & Immunotherapeutics
- CD4 + T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8 + T-cell Targeting of HER2/ neu –Expressing Cancers
- (2015) Jashodeep Datta et al. Cancer Immunology Research
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- DNA vaccine for cancer immunotherapy
- (2015) Benjamin Yang et al. Human Vaccines & Immunotherapeutics
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Current status of autologous breast tumor cell-based vaccines
- (2014) Samantha L Kurtz et al. Expert Review of Vaccines
- Dendritic cell-based vaccines: clinical applications in breast cancer
- (2014) Lucia Gelao et al. Immunotherapy
- Peptide-Pulsed Dendritic Cells Have Superior Ability to Induce Immune-Mediated Tissue Destruction Compared to Peptide with Adjuvant
- (2014) Dilan Dissanayake et al. PLoS One
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses
- (2013) Y Xie et al. CANCER GENE THERAPY
- Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures
- (2013) E-K Kim et al. GENE THERAPY
- Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
- (2013) Claudia Marcela Diaz-Montero et al. Journal of Translational Medicine
- New viruses for cancer therapy: meeting clinical needs
- (2013) Tanner S. Miest et al. NATURE REVIEWS MICROBIOLOGY
- Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
- (2013) D Raina et al. ONCOGENE
- Allogeneic tumor cell vaccines
- (2013) Sanjay Srivatsan et al. Human Vaccines & Immunotherapeutics
- Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
- (2013) Patrizia Nanni et al. PLoS Pathogens
- Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
- (2013) Cristina Marchini et al. Frontiers in Oncology
- CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC
- (2012) T Nguyen-Hoai et al. CANCER GENE THERAPY
- Filamentous Bacteriophage Fd as an Antigen Delivery System in Vaccination
- (2012) Antonella Prisco et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The future of human DNA vaccines
- (2012) Lei Li et al. JOURNAL OF BIOTECHNOLOGY
- The GP2 peptide: A HER2/neu-based breast cancer vaccine
- (2012) Kevin S. Clive et al. JOURNAL OF SURGICAL ONCOLOGY
- Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens
- (2012) Douglas S. Watson et al. VACCINE
- Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients
- (2011) Elizabeth A. Mittendorf et al. CANCER
- Clinical development directions in oncolytic viral therapy
- (2011) R M Eager et al. CANCER GENE THERAPY
- CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model
- (2011) T Nguyen-Hoai et al. CANCER GENE THERAPY
- Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells
- (2011) Fatemeh Mosaffa et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Anti-HER2 vaccines: new prospects for breast cancer therapy
- (2010) Maha Zohra Ladjemi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model
- (2010) Nafiseh Pakravan et al. CELL STRESS & CHAPERONES
- Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population
- (2010) J Behravan et al. INDIAN JOURNAL OF CANCER
- Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
- (2010) Håkan Norell et al. Journal of Translational Medicine
- Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population
- (2010) Azam Khedri et al. MOLECULAR BIOLOGY REPORTS
- Nanoparticle Delivery Systems in Cancer Vaccines
- (2010) Yogita Krishnamachari et al. PHARMACEUTICAL RESEARCH
- Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients
- (2009) Mark G. Carmichael et al. CANCER
- Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
- (2009) D. Raina et al. CANCER RESEARCH
- Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators
- (2009) Pernille Nordly et al. Expert Opinion on Drug Delivery
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial
- (2009) Ritesh Patil et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Dexamethasone Downregulates BCRP mRNA and Protein Expression in Breast Cancer Cell Lines
- (2009) Fatemeh Elahian et al. ONCOLOGY RESEARCH
- Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
- (2009) L. Menotti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preparation and anti-tumor evaluation of polyactin A microparticles from supercritical CO2 processing
- (2008) Jianhong Bi et al. APPLIED SURFACE SCIENCE
- Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors
- (2008) Y Gao et al. CANCER GENE THERAPY
- Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel
- (2008) Shinichi Kageyama et al. CANCER SCIENCE
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Aptamers in Immunotherapy
- (2008) Claudia M. Dollins et al. HUMAN GENE THERAPY
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started